

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL:

USAN (yy-153)

DELDEPREVIR SODIUM

PRONUNCIATION

del de' pre vir


THERAPEUTIC CLAIM

Treatment of Hepatitis C

CHEMICAL NAMES

1. Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5*H*)-carboxamide, *N*-(cyclopropylsulfonyl)-6-[2-(3,3-difluoro-1-piperidinyl)-2-oxoethyl]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-8-methyl-2-[4-(1-methylethyl)-2-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, sodium salt (1:1), (2*R*,6*R*,12*Z*,13a*S*,14a*R*,16a*S*)-
2. Sodium (cyclopropylsulfonyl){[(2*R*,6*R*,12*Z*,13a*S*,14a*R*,16a*S*)-6-[2-(3,3-difluoropiperidin-1-yl)-2-oxoethyl]-2-({7-methoxy-8-methyl-2-[4-(1-methylethyl)thiazol-2-yl]quinolin-4-yl}oxy)-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-14a(5*H*)-yl]formyl]azanide

STRUCTURAL FORMULA



MOLECULAR FORMULA

C₄₅H₅₅F₂N₆NaO₈S₂

MOLECULAR WEIGHT

933.1

TRADEMARK

None as yet

SPONSOR

Achillion Pharmaceuticals, Inc.

CODE DESIGNATION

ACH-0142684.Na, ACH-2684.Na

CAS REGISTRY NUMBER

1298053-61-8

NOTE: This adoption statement replaces adoption N12/18 and the name *neceprevir sodium* is hereby rescinded.